On October 5, 2026, Alector, a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, announced it has entered into an exclusive global licensing agreement with Genentech, a member of the Roche Group, granting Genentech worldwide rights to develop and commercialize Alector’s AL050 program, its brain-penetrant engineered glucocerebrosidase (GCase) ERT. Under the terms of the agreement, Alector will receive an upfront payment of $100 million and is also eligible to receive tiered royalties on net sales and additional payments of up to $1.17 billion upon the achievement of development, regulatory, and commercial milestones. Wilson Sonsini Goodrich & Rosati advised Alector on the transaction.

The Wilson Sonsini team that advised Alector on the transaction includes:

Technology Transactions
Matt Wiltermuth
Colin Bosch
James Dunlop

Corporate
Michael Coke
Christina Poulsen

Patents and Innovations
Mike Hostetler
Alicia Umpierre

Tax
Myra Sutanto Shen
Anjali Krishnan

For more information, please see Alector’s news release. Additional coverage can be found on Fierce Biotech.